Allergan Adds Device To Glaucoma Portfolio

The pharmaceutical firm is entering the highly touted micro-invasive glaucoma surgery space with an acquisition of AqueSys, adding a device to its established portfolio of glaucoma drugs.

Allergan PLC is entering the micro-invasive glaucoma surgery (MIGS) space with an agreement to buy the clinical-stage company AqueSys Inc.

AqueSys’ XEN45 device is a soft shunt designed to be implanted in the subconjunctival space in the eye through a...

More from Archive

More from Medtech Insight